TABLE. Tuberculosis (TB) symptom-screening and TB preventive treatment (TPT) outcomes for persons living with human immunodeficiency virus (HIV) infection receiving antiretroviral therapy (ART), by country — 16 countries supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), 2017–2019.
| Country (estimated no. of persons living with HIV infection) | No. of persons living with HIV infection receiving ART through PEPFAR* | No. (%) of ART patients screened for TB | No. of ART patients screened negative for TB | No. expected to complete TPT† | No. (%) completed TPT |
|---|---|---|---|---|---|
|
Group 1: TB screening during period 1
§
; TPT completion during period 2
¶
| |||||
| Cameroon (510,000) |
176,927 |
130,795 (74) |
126,893 |
276 |
41 (15) |
| DRC (390,000) |
65,385 |
57,938 (89) |
55,302 |
26,402 |
17,157 (65) |
| Eswatini (210,000) |
150,987 |
137,590 (91) |
134,638 |
9,394 |
7,744 (82) |
| Ethiopia (610,000) |
434,897 |
386,419 (89) |
334,407** |
14,297 |
11,490 (80) |
| Haiti (150,000) |
91,845 |
54,530 (59) |
51,662 |
7,827 |
3,864 (49) |
| Kenya (1,500,000) |
1,041,326 |
995,264 (96) |
915,577 |
130,535 |
105,550 (81) |
| Lesotho (320,000) |
151,799 |
136,522 (90) |
132,230 |
5,298 |
765 (14) |
| Mozambique (2,100,000) |
995,547 |
680,901 (68) |
633,787 |
87,753 |
12,160 (14) |
| Namibia (200,000) |
165,965 |
58,318 (35) |
57,501 |
5,944 |
5,017 (84) |
| Nigeria (3,100,000) |
772,510 |
660,501 (86) |
606,726 |
45,093 |
34,840 (77) |
| South Africa (7,200,000) |
3,256,407†† |
—§§ |
—§§ |
121,484 |
52,958 (44) |
| Tanzania (1,500,000) |
932,425 |
893,280 (96) |
880,954 |
59,660 |
27,264 (46) |
| Uganda (1,300,000) |
993,070 |
960,999 (97) |
77,857** |
17,609 |
12,454 (71) |
| Vietnam (250,000) |
87,702 |
43,173 (49) |
30,766** |
3,743 |
3,221 (86) |
| Zambia (1,100,000) |
745,127 |
382,872 (51) |
373,386 |
10,866 |
7,582 (70) |
| Zimbabwe (1,300,000) |
849,310 |
338,535 (40) |
287,622** |
198 |
144 (73) |
|
Subtotal, period 1
|
10,911,229
|
5,917,637 (54)
|
4,699,308
|
546,379
|
302,251 (55)
|
|
Group 2: TB screening during period 2¶; TPT completion during period 3¶¶
| |||||
| Cameroon |
177,434 |
148,143 (83) |
143,684 |
1,385 |
888 (64) |
| DRC |
72,143 |
65,127 (90) |
39,356** |
14,714 |
8,426 (57) |
| Eswatini |
169,272 |
163,736 (97) |
158,348 |
10,538 |
7,929 (75) |
| Ethiopia |
451,436 |
384,226 (85) |
262,289** |
16,715 |
13,448 (80) |
| Haiti |
95,697 |
81,280 (85) |
73,622 |
8,229 |
4,839 (59) |
| Kenya |
1,066,579 |
1,022,624 (96) |
951,497 |
98,271 |
73,462 (75) |
| Lesotho |
190,569 |
154,029 (81) |
149,491 |
2,926 |
380 (13) |
| Mozambique |
1,077,726 |
696,643 (65) |
673,895 |
94,832 |
21,124 (22) |
| Namibia |
177,062 |
112,221 (63) |
49,317** |
5,660 |
5,276 (93) |
| Nigeria |
799,718 |
746,588 (93) |
697,815 |
61,817 |
46,547 (75) |
| South Africa |
3,446,694 |
2,540,588 (74) |
2,440,961 |
124,520 |
65,526 (53) |
| Tanzania |
995,953 |
968,540 (97) |
939,591 |
64,279 |
31,534 (49) |
| Uganda |
1,031,846 |
999,492 (97) |
185,494** |
8,246 |
5,248 (64) |
| Vietnam |
91,457 |
74,761 (82) |
11,123** |
10,601 |
7,364 (69) |
| Zambia |
801,669 |
296,204 (37) |
289,812 |
17,225 |
13,233 (77) |
| Zimbabwe |
939,164 |
839,120 (89) |
766,572 |
290 |
134 (46) |
|
Subtotal, period 2
|
11,584,419
|
9,293,322 (80)
|
7,832,867
|
540,248
|
305,358 (57)
|
|
Group 3: TB screening during period 3¶¶; TPT completion during period 4***
| |||||
| Cameroon |
188,979 |
158,850 (84) |
152,459 |
8,526 |
3,324 (39) |
| DRC |
88,488 |
85,026 (96) |
54,051** |
12,743 |
9,169 (72) |
| Eswatini |
175,912 |
167,276 (95) |
164,285 |
12,069 |
9,281 (77) |
| Ethiopia |
460,565 |
427,242 (93) |
346,031** |
13,976 |
11,239 (80) |
| Haiti |
101,597 |
87,865 (86) |
84,588 |
10,454 |
6,095 (58) |
| Kenya |
1,084,100 |
1,104,679 (102) |
981,037 |
58,452 |
52,792 (90) |
| Lesotho |
218,493 |
177,416 (81) |
173,572 |
5,462 |
1,839 (34) |
| Mozambique |
1,107,749 |
824,247 (74) |
798,227 |
83,897 |
23,022 (27) |
| Namibia |
179,844 |
88,706 (49) |
47,487** |
10,425 |
9,388 (90) |
| Nigeria |
807,094 |
604,596 (75) |
575,959 |
152,528 |
120,787 (79) |
| South Africa |
3,515,553††† |
2,986,266 (85) |
2,896,646 |
139,721 |
66,045 (47) |
| Tanzania |
1,075,346 |
1,063,362 (99) |
1,041,380 |
126,352 |
96,737 (77) |
| Uganda |
1,120,271 |
1,067,117 (95) |
409,084** |
19,103 |
13,419 (70) |
| Vietnam |
122,822 |
133,101 (108) |
28,277** |
3,782 |
3,430 (91) |
| Zambia |
894,090 |
514,926 (58) |
524,954 |
37,761 |
26,859 (71) |
| Zimbabwe |
968,690 |
653,288 (67) |
604,467 |
23,270 |
17,836 (77) |
|
Subtotal, period 3
|
12,109,593
|
10,143,963 (84)
|
8,882,504
|
718,521
|
471,262 (66)
|
| Total, periods 1–3 | 34,605,241 | 25,354,922 (73) | 21,414,679 | 1,805,148 | 1,078,871 (60) |
Abbreviation: DRC = Democratic Republic of the Congo.
* Snapshot at end of the reporting period accounts for net gains (e.g., new HIV diagnoses) and losses (e.g., deaths and patients lost to follow-up).
† Number of ART patients expected to complete TPT approximates number of TPT initiations. If the patient is prescribed 6 months of daily isoniazid, the patient is expected to complete treatment during the reporting period subsequent to that of initiation. Otherwise, if prescribed a shorter rifamycin-based course, the patient might be expected to complete treatment during the initiation reporting period.
§ April 1–September 30, 2017.
¶ October 1, 2017–March 31, 2018.
** >10% of TB symptom-screening results were missing.
†† The South African National Department of Health (NDOH) receives PEPFAR support for health system strengthening and other non–patient care activities. NDOH annually reports ART patients in its care but does not report TPT initiation or completion. Therefore, ART patients reported by NDOH were subtracted from South Africa totals in period 1 (779,313) and in period 3 (900,463) to include data reported only by South African partners that received PEPFAR support for delivering health care services.
§§ Indicator not reported.
¶¶ April 1, 2018–September 30, 2018.
*** October 1, 2018–March 31, 2019.
††† The number of ART patients in South Africa was adjusted in Period 3 to include only data from sites receiving investment for direct health care service delivery.